

Determined to realize a future in which people with cancer live longer and better than ever before



3Q21 EARNINGS PRESENTATION

Forward-looking statements disclosure

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding future operations, financial results and the financial condition of Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company"), including financial position, strategy and plans, the progress, timing, clinical development and scope of clinical trials and the reporting of clinical data for Syndax's product candidates, and Syndax's expectations for liquidity and future operations, are forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical site activation rates or clinical trial enrollment rates that are lower than expected, changes in expected or existing competition, failure of our collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. Moreover, Syndax operates in a very competitive and rapidly changing environment. Other factors that may cause our actual results to differ from current expectations are discussed in Syndax's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. New risks emerge from time to time. It is not possible for Syndax's management to predict all risks, nor can Syndax assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied. Except as required by law, neither Syndax nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. Syndax undertakes no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in Syndax's expectations.

Syndax pipeline targets indications with significant unmet need

Global partnership
signed with Incyte

Menin Inhibitor Program (SNDX-5613)

- NPM1 and MLLr acute leukemias
- Pivotal trials (AUGMENT) ongoing
- Oral presentation of Ph1 data @ ASH
- Accelerated path to approval

Anti-CSF-1R Program (Axatilimab)

- Macrophage driven diseases
- Pivotal trial (AGAVE-201) ongoing
- Oral presentation of Ph1/2 data @ ASH
- cGVHD data validates target across additional fibrotic opportunities


Development Opportunities

- Focused on expanding clinical pipeline through development and in-licensing

AUGMENT-101 registration trials underway in 3 distinct patient populations

AUGMENT-101
R/R MLLr or
mNPM1
acute
leukemia

Dose: 163mg BID
with any strong
CYP3A4 inhibitor



** Patients taken to HSCT can restart treatment with SNDX-5613 post-Transplant*

ASH abstract for AUGMENT-101 highlights robust clinical activity

Summary of ASH abstract (June 2021 data cut)


Selected baseline demographics	Overall (n = 54)
Median age	49 years
# Prior lines of therapy, Median (Range)	3 (1-12)
# Patients with prior venetoclax	31 (57%)
# Patients with prior transplants	24 (44%)
Best Overall Response	Efficacy eval
CRc (CR+CRh+CRp+CRi/MLFS)	20/45 (44%)
CRc MRD-	14/20 (70%)
CR+CRh	10/45 (22%)
Duration of response (with 3.2 mo follow up)	5.2 mo

Eytan Stein to present updated data on Monday Dec. 13 @ 3:15 pm

Trials testing expanded opportunities for SNDX-5613 to initiate in 1H22

BEAT-AML: Frontline Ven/Aza combo

Phase 1/3; Frontline
mNPM1 or MLLr AML
SNDX-5613 + Ven/Aza




Primary Endpoints:

- RP2D of combo
- CR/CRh rate, MRD- rate, OS

AUGMENT-102: R/R Chemo combo

Phase 1; Relapsed or refractory
mNPM1 or MLLr AML/ALL
SNDX-5613 + chemo




Primary Endpoints:

- Safety, tolerability, RP2D of combo



INTERCEPT: MRD-progression in AML

Phase 1; Relapsed or refractory
mNPM1 or MLLr AML/ALL
SNDX-5613 + chemo



Primary Endpoints:

- MRD- rate


SNDX-5613: moving into frontline meaningfully expands market potential with additional patients and increasing duration of Tx

Potential best/first-in-class agent

- Clear efficacy in refractory, advanced NPM1 and MLLr acute leukemia
- High percentage of MRD negative responses

Profile supports use in frontline and maintenance

- Well-tolerated safety profile, no discontinuations due to treatment related AE
- Preclinical data supports combos with venetoclax¹, chemotherapy²
- Pediatric formulation established



1. Carter, B., et al., Blood 2021, 2. Data on file

A broad, long-term, global collaboration between Syndax and Incyte to accelerate and maximize the development of axatilimab

- \$117M upfront
- \$35M equity @ 30% premium
- Up to \$450M in additional milestones



Global co-dev for all indications;
SNDX funds 45% of global trials,
INCY funds 100% of regional trials

50:50 profit split; SNDX has option to
provide up to 30% of US sales force

SNDX to receive double-digit tiered
royalties on ex- US sales

Combo with JAK inhib in cGVHD and
IPF POC trials planned for 2022

ASH abstract highlights axatilimab's broad efficacy and tolerability

Summary of ASH abstract (June 2021 data cut)

Selected baseline demographics	Overall (n = 40)
Median age (range)	59 years (16-73)
# Prior lines of therapy, Median (Range)	4 (1-11)
# Patients with prior ibrutinib	25 (63%)
# Patients with prior ruxolitinib	21 (53%)
# Patients with prior belumosudil	8 (20%)
Best Overall Response	Efficacy eval
Overall Response rate, all doses	25/38 (66%)
Overall Response rate, 1 mg/kg q2wk dose	18/24 (75%)

Stephanie Lee to present updated data on Saturday Dec. 11 @ 3 pm



AGAVE-201 : ongoing global pivotal trial for axatilimab in chronic GVHD

Inclusion criteria:

- 6 years and older
- Recurrent or refractory active cGVHD after at least 2 lines of systemic therapy



Primary Endpoint: Objective Response Rate (ORR) by 2014 NIH GVHD Criteria

Key Secondaries: Duration of response, improvement in modified Lee Symptom Scale


Axatilimab: moving up the treatment paradigm in cGVHD and into new indications meaningfully expands market potential

Potential best/first-in-class agent

- Clear efficacy in chronic Graft vs Host disease
- Clinical evidence supporting reversal of fibrosis

Profile supports expanded use within cGVHD and additional indications

- Well-tolerated safety profile, no discontinuations due to treatment related AE
- Only agent in development targeting monocyte derived macrophages
- Preclinical data supporting benefit in other fibrotic indications, e.g., IPF



Proven ability to build the pipeline

Business development continues to be
a core strength of our business

Clinical development leadership enables
competitive advantage

Established relationships enhance
identification and access to quality assets


From UCB

Axatilimab



From Allergan/Vitae

Menin-MLL
inhibitors



Financial highlights and FY 2021 financial guidance

Ticker	SNDX (NASDAQ)
Cash and short-term investments (as of September 30, 2021)	\$229.7 million
Shares Outstanding* (as of September 30, 2021)	52.2 million
2021 Operating Expense Guidance	
FY 2021	
Research and Development	\$90-100 million
Total Operating Expenses [^]	\$110-120 million

* Includes 48.9 million common shares and pre-funded warrants to purchase 3.3 million common shares;

[^] Includes ~\$13 million non-cash stock compensation expense for the full year

Thank you. Questions?

Syndax 